Selected work

Case studies. Decision-ready evidence.

Selected outputs from Brown Biotech engagements — structured as the evidence trail, the challenge, the approach, and the next action. Each one reflects the same brief-first workflow used for every client.

Request a Paid Brief View service lanes

Briefs, analyses, and evidence trails.

Three selected engagements — structured the same way every Brown Biotech brief is structured.

ARP Pipeline · Senolytic

ARP-NAAA Senolytic Target Brief

Pharmaceutical company entering the senescence space · 6 weeks

Route: peptide-service

Challenge

A pharmaceutical company with an established oncology franchise was exploring anti-aging indications and needed a structured brief on the NAAA (N-acylethanolamine acid amidase) pathway before committing to a due diligence process. The internal team had limited bandwidth and needed an external evidence review to frame the opportunity.

Approach

Structured literature brief: NAAA biology and its role in senescent cell clearance, current competitive landscape for senolytic approaches, a gap analysis identifying where the client could enter without competing head-on with established senolytic programs. The brief was structured as a decision-ready document covering biology, competitive position, and a recommended next step.

Evidence stack

  • PubMed: NAAA pathway biology and substrate selectivity (2018–2024)
  • ClinicalTrials.gov: active senolytic programs and recruitment status
  • ChEMBL: NAAA inhibitor structures and activity data
  • Competitive landscape: 6 programs in senolytic development
  • Patent landscape: key filings in NAAA-targeted approaches

Outcome

Delivered a 14-page evidence brief with a competitive gap map and three actionable next steps. The brief was used to support an internal go/no-go decision and subsequently shared with the business development team. Two of the three recommended next steps are now in active scoping.

Next action

The client is evaluating a deeper engagement to scope a potential partnership with an academic group working on NAAA biology. A peptide-service brief for the NAAA-targeting peptide library is also being discussed.

Interested in a similar brief?

peptide-service lane · ARP-NAAA work

Request a Brief
peptide-service · Scope

Peptide-Service Scope for a Pharma Partner

Global pharmaceutical company evaluating peptide synthesis vendors · 3 weeks

Route: peptide-service

Challenge

A global pharmaceutical company needed to evaluate a peptide synthesis partner for a critical peptide drug substance. The internal procurement team needed an independent evidence brief to support the vendor selection process — including quality assessments, regulatory compliance records, and capacity benchmarks.

Approach

Defined the vendor evaluation framework, sourced evidence across three candidate vendors, compiled a regulatory compliance assessment, and produced a structured brief covering quality, capacity, and pricing benchmarks. The brief structured the evaluation as a decision-ready document rather than a generic vendor comparison.

Evidence stack

  • Vendor capacity and capability records (public + confidential)
  • Regulatory filing history (DMFs, CTD modules)
  • Peer-reviewed literature citing vendor work
  • Pricing benchmarks from comparable engagements
  • Internal procurement constraints and decision criteria

Outcome

The brief was used as the primary decision artifact in a vendor selection meeting. The client selected the recommended vendor and cited the structured evidence trail as the key reason the decision was made without extended internal debate.

Next action

The client is now evaluating whether to commission a second brief covering the synthesis scale-up plan for the selected peptide candidate, which would move into a project-tier engagement.

Interested in a similar brief?

peptide-service lane · Peptide-Service work

Request a Brief
biostatx · Multi-omics

Fibrosis / IPF Multi-omics Brief

Academic respiratory research group with a translational interest · 8 weeks

Route: biostatx

Challenge

An academic group studying idiopathic pulmonary fibrosis (IPF) had multi-omics data (transcriptomics, proteomics, and clinical chemistry) from a 60-subject cohort. They needed a structured integration analysis plan before submitting a grant renewal — and needed to demonstrate that the analytical approach was rigorous enough to support a preclinical-to-clinical translation question.

Approach

Full data inventory across the three modalities, alignment strategy for batch effects and missingness, unsupervised clustering framework design, and a formal statistical analysis plan covering primary endpoint definition, power calculations, and sensitivity analysis framework. The deliverable was structured as a grant-ready methods section plus a decision tree for the analysis execution.

Evidence stack

  • GEO: IPF transcriptomics reference datasets (GSE93606, GSE110147)
  • Proteomics raw data from the 60-subject cohort
  • Clinical chemistry panel: lung function indices (FVC, DLCO)
  • Literature: IPF multi-omics integration approaches (2020–2024)
  • Simulation study: power calculations for three endpoint scenarios

Outcome

Grant renewal submitted with the statistical analysis plan as a core appendix. The review committee cited the analytical rigor as a differentiating factor in the scoring. The group has since commissioned a follow-on biostatx engagement for the actual analysis execution.

Next action

The group is preparing to submit a second brief for the analysis execution phase — covering the full multi-omics integration and the subsequent manuscript preparation. This would run as a project-tier engagement.

Interested in a similar brief?

biostatx lane · Fibrosis work

Request a Brief

How every engagement starts.

Every Brown Biotech engagement — including the work above — begins with a paid brief. The brief defines the lane, the owner, the evidence stack, and the next action before anything moves forward.

Request a Paid Brief View all service lanes